Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Myelomonocytic, Chronic 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × bisantrene × Clear all
NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05456269 2023-10-03

BISECT

Racura Oncology Ltd

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03820908 2020-08-07

Bisantrene for Relapsed /Refractory AML

Sheba Medical Center

Phase 2 Completed
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡